LyncBio Therapeutics

LyncBio Therapeutics was founded in September 2023, relying on a proprietary core ADC technology platform. The company’s key pipeline for the treatment of intestinal inflammation is advancing rapidly, with independent ADC research and development, GMP production, and toxicology studies completed within two years. It has now entered the IND application stage, with the potential to fill the clinical gap for ADC drugs in this therapeutic area globally. At the same time, multiple other products in the company’s pipeline are in the early stages of development, covering indications such as multiple sclerosis, pan-cancer solid tumors, and multiple myeloma, forming an advantageous layout led by next-generation ADC technology and driven by multi-pipeline collaborative development.